OMH Osmetech

 

TIDMOMH 
 
 
Osmetech PLC 
14 May 2009 
 
? 
14 May 2009 
 
 
Osmetech plc ("Osmetech" or the "Company") 
 
 
Osmetech's eSensor XT-8 platform wins Medical Design Excellence Award 
 
 
Osmetech plc (OMH.L), the international molecular diagnostics company, announces 
that it has received a Medical Design Excellence Award for innovative device 
design. The Company has received a 2009 Medical Design Excellence Award for its 
eSensor  XT-8 molecular diagnostics platform, initially launched with a Warfarin 
Sensitivity Test. 
 
 
The FDA-cleared device produces results in less than 30 minutes detecting 
multiple genetic markers from a prepared patient sample. Using proprietary 
electro-chemical technology, the self-contained cartridge consumable contains 72 
gold-plated electrodes, each acting as independent DNA microsensors on a printed 
circuit board. 
 
 
The instrument provides an easy-to-use graphical, touch screen interface, a 
small footprint, requires limited operator training, low maintenance and no 
instrument calibration. Each cartridge slot operates independently supporting 
the use of a wide variety of tests and the system's modular design enables the 
capacity requirements of high throughput users to be met. 
 
 
James White, Chief Executive Officer, Osmetech plc, said: 
 
 
"We are delighted that our eSensor XT-8 System and Warfarin Sensitivity Test has 
received this independent award. This is further recognition for our innovative, 
practical and cost-effective platform which is rapidly gaining market acceptance 
illustrated by our selection as principal supplier of Warfarin Sensitivity tests 
for a major new US trial sponsored by the US National Heart, Lung, and Blood 
Institute." 
 
 
About the Medical Design Excellence Award competition 
 
 
The Medical Design Excellence Awards competition is organized and presented by 
Canon Communications LLC (Los Angeles) and is the only awards program that 
exclusively recognizes contributions and advances in the design of medical 
products. Entries are evaluated on the basis of their design and engineering 
features, including innovative use of materials, user-related functions that 
improve healthcare delivery and change traditional medical attitudes or 
practices, features that provide enhanced benefits to the patient and the 
ability of the product development team to overcome design and engineering 
challenges so that the product meets its clinical objectives. 
 
 
A comprehensive review of the entries was performed by a multidisciplinary panel 
of third-party jurors with expertise in biomedical engineering, human factors, 
industrial design, medicine and diagnostics. 
 
 
About warfarin sensitivity testing 
 
 
Warfarin is an oral anticoagulant widely used for the prevention of thrombotic 
events and to treat a confirmed episode of venous thrombosis, with approximately 
2 million new patients each year in the US alone. Although highly effective, 
warfarin's usability is limited by a narrow therapeutic range combined with a 
pronounced interindividual variability in the dose required for adequate 
anticoagulation. Clinical use of warfarin is further complicated by a 
substantial risk for hemorrhagic side effects, which is increased in patients 
with low-dose requirements. Warfarin is the second-most-likely drug, after 
Digoxin, to cause adverse events requiring hospitalization. 
 
 
About Osmetech plc 
(www.osmetech.com) 
 
 
Osmetech plc is an AIM-listed public company on the London Stock Exchange. The 
Company is a fast developing, international diagnostics business with operations 
in Boston and Pasadena in the US, serving the high growth molecular diagnostic 
market targeting hospitals and reference laboratories. 
 
 
Osmetech has a strong portfolio of over 200 issued and pending patents and has 
launched its first generation eSensor 4800 platform, an electrochemistry-based 
array system, together with an FDA cleared in vitro diagnostic test for Cystic 
Fibrosis carrier detection. 
 
 
Osmetech's second generation platform, the eSensor XT-8 received FDA 510(k) 
clearance in July 2008 together with our eSensor Warfarin Sensitivity Test. 
These products are now being marketed in the U.S. together with a 2C9 Genotyping 
Test for drug metabolism and a Cystic Fibrosis carrier detection test which are 
both available for research use purposes only. 
 
 
In April 2009, Osmetech signed a five-year distribution agreement with Fisher 
HealthCare, a part of Thermo Fisher Scientific, whereby Fisher HealthCare will 
distribute Osmetech's eSensor XT-8 instrument platform and molecular diagnostic 
tests and consumables in the U.S. 
 
 
The eSensor XT-8 System is designed to support a broad menu of tests and 
Osmetech has scheduled for commercial launch a number of further tests 
including: extended warfarin panel with the proprietary 4F2 marker, venous 
thrombosis (Factor II, Factor V Leiden and MTHFR) and the RESPLEX II respiratory 
pathogen assay in-licensed from Qiagen. The System provides accurate results 
while minimizing technician involvement and its features compare favorably to 
those of other molecular detection systems. Its ease of use, readily 
interpretable results, speed and low maintenance are particularly suited to the 
needs of the decentralizing market. 
 
 
Osmetech plc +44 (0)207 849 6027 
James White, Chief Executive Officer    +1 626 463 2000 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRACKNKNFBKDDPD 
 

Osmetech (LSE:OMH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Osmetech (LSE:OMH)
Gráfica de Acción Histórica
De May 2023 a May 2024